Oxybutynin IVR - Juniper Pharmaceuticals

Drug Profile

Oxybutynin IVR - Juniper Pharmaceuticals

Alternative Names: JNP 0101; JNP-0101 intravaginal ring; Oxybutynin IVR

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juniper Pharmaceuticals
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Overactive bladder

Most Recent Events

  • 18 Sep 2017 Oxybutynin IVR - Juniper Pharmaceuticals is available for licensing as of 18 Sep 2017. http://www.juniperpharma.com/
  • 18 Sep 2017 Suspended - Preclinical for Overactive bladder in USA (Vaginal)
  • 11 Jan 2017 Juniper Pharmaceuticals announces intention to submit IND application for oxybutynin to the US FDA in 2017 (Juniper Pharmaceuticals website, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top